Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 5/20 | 0.58 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15247914 | 0.99 | DHODH (0.60) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL15364116 | 0.91 | DHODH (0.69) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL15364121 | 0.91 | DHODH (0.69) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL29572464 | 0.90 | DHODH (0.71) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL15247881 | 0.88 | APP (0.67) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL19261658 | 0.87 | DHODH (0.56) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL18128996 | 0.87 | DHODH (0.59) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL19261676 | 0.85 | DHODH (0.54) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL2732257 | 0.83 | DHODH (0.57) | PTGESALOX5PTGS1PTGS2DHODH | |
| SCHEMBL2732259 | 0.83 | DHODH (0.57) | PTGESALOX5PTGS1PTGS2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857010-B1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | INST OF MITOCHONDRIA SCIENCE INC (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-2857010-B1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | INST OF MITOCHONDRIA SCIENCE INC (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI INC. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2857010-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI Inc. (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857010-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI Inc. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013180140-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | エヌエーアイ株式会社 (JP) | 2013-12-05 | — | — | WO | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2636663-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | aRigen Pharmaceuticals, Inc. (JP) | 2013-09-11 | — | — | EP | disclosed |
| EP-2636663-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | aRigen Pharmaceuticals, Inc. (JP) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012060387-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | アリジェン製薬株式会社 (JP) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | PTGES 2938/4885ALOX5 1012/4885PTGS1 714/4885 |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | CBR3, CBR1, DHX35 | PTGES 2891/4885ALOX5 79/4885PTGS1 1701/4885 |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | PTGES 2995/4885ALOX5 928/4885PTGS1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.